|
gptkbp:instanceOf
|
gptkb:drug
leukotriene receptor antagonist
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
R03DC03
|
|
gptkbp:bioavailability
|
64%
|
|
gptkbp:brand
|
gptkb:Singulair
Montelo-10
|
|
gptkbp:CASNumber
|
151767-02-1
|
|
gptkbp:chemicalClass
|
quinolines
|
|
gptkbp:contraindication
|
hypersensitivity to Montelukast
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
2.7–5.5 hours
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:firstSynthesized
|
1993
|
|
gptkbp:form
|
gptkb:tablet
chewable tablet
granules
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasMolecularFormula
|
C35H36ClNO3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Montelukast
|
|
gptkbp:IUPACName
|
2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanyl}methyl)cyclopropyl]acetic acid
|
|
gptkbp:KEGGID
|
D08123
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks leukotriene D4 at the cysteinyl leukotriene receptor (CysLT1)
|
|
gptkbp:MedlinePlusID
|
a600014
|
|
gptkbp:meltingPoint
|
137–139 °C
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP2C9, CYP2C8)
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
4445532
5281040
DB00471
CHEMBL695
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
abdominal pain
headache
cough
neuropsychiatric effects
|
|
gptkbp:solubility
|
practically insoluble in water
|
|
gptkbp:UNII
|
QF8SVZ843E
|
|
gptkbp:usedFor
|
asthma
allergic rhinitis
exercise-induced bronchoconstriction
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|